

**Supplementary Table 1. Summary of the clinicopathological characteristics of the patients with lung adenocarcinoma examined for *EZH2* expression and KRAS mutations (N=265)**

	Category	Frequency Count	Percent of Total Frequency
Gender	Female	142	53.58
	Male	123	46.42
Smoking Status	Current	97	36.6
	Former	123	46.42
	Never	45	16.98
T Stage (IASLC)	T1	95	35.85
	T2	121	45.66
	T3	39	14.72
	T4	10	3.77
N Stage (IASLC)	N0	187	70.57
	N1	35	13.21
	N2	42	15.85
	N3	1	0.38
TNM Stage IASLC	I	141	53.21
	II	58	21.89
	III	55	20.75
	IV	11	4.15
Adjuvant Therapy	No	147	55.47
	Yes	105	39.62
Vital Status	Alive	129	48.68
	Dead	136	51.32
Recurrence	No	145	54.72
	Yes	120	45.28
KRAS mutation	Negative (wild-type)	183	69.06
	Positive (mutant)	82	30.94
	Codon 12	72	87.80
	Codon 13	10	12.19
	Cys substitutions	40	48.78
	Asp substitutions	16	19.51
	Val substitutions	14	17.07
	Other substitutions	12	14.63

IASLC; International Association for the Study of Lung Cancer